FDA OKs Merck’s Keytruda for highly mutating forms of colorectal cancer

The FDA approves Merck’s (MRK +1.0%) PD-1 inhibitor Keytruda (pembrolizumab) for the first-line treatment of patients with unresectable/metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, rapidly mutating forms of the disease that have poor prognoses.

The company says Keytruda is the first immunotherapy to receive the FDA nod for these patients in a first-line setting.

https://seekingalpha.com/news/3587077-fda-oks-mercks-keytruda-for-highly-mutating-forms-of-colorectal-cancer